TransMedics Group, Inc. 8-K

What Happened

• On February 27, 2026, TransMedics Group, Inc. announced additional information about the financial effects of releasing the company’s U.S. valuation allowance on deferred tax assets as they relate to its previously reported results for the quarter ended December 31, 2025. The company furnished a press release as Exhibit 99.1 to the Form 8‑K.

Key Details

• Filing date: February 27, 2026 (Form 8‑K Item 2.02).
• Subject: Release of the U.S. valuation allowance on deferred tax assets and its impact on previously reported quarterly results (quarter ended Dec 31, 2025).
• The press release providing the additional information is furnished as Exhibit 99.1 to the 8‑K.
• The 8‑K states the furnished information is not being “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless explicitly stated.

Why It Matters

• A release of a valuation allowance on deferred tax assets can materially change reported tax expense, net income, and earnings per share for the affected period, so this update could alter investors’ view of TransMedics’ recent quarterly results.
• Investors should read the furnished press release (Exhibit 99.1) and any related disclosures to determine the magnitude of the adjustments and any effects on reported earnings, tax position, or future cash flows.